scholarly journals Circulating Levels of Biologically Active and Immunoreactive Intact Parathyroid Hormone in Human Newborns

1991 ◽  
Vol 29 (2) ◽  
pp. 201-207 ◽  
Author(s):  
Lewis P Rubin ◽  
James T Posillico ◽  
Constantine S Anast ◽  
Edward M Brown
Keyword(s):  
Parathyroid Hormone ◽  
Biologically Active ◽  
Intact Parathyroid Hormone ◽  
Circulating Levels

scholarly journals Circulating levels of biologically active parathyroid hormone in rheumatic diseases.

1982 ◽  
Vol 41 (6) ◽  
pp. 569-573 ◽  
Author(s):  
J Dunham ◽  
B E Bourke ◽  
L Bitensky ◽  
J Chayen ◽  
N Loveridge ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Rheumatic Diseases ◽  
Biologically Active ◽  
Circulating Levels

Circulating levels of immunoreactive parathyroid hormone-related protein and intact parathyroid hormone in human fetuses and newborns

1996 ◽  
Vol 134 (4) ◽  
pp. 437-442 ◽  
Author(s):  
Nicholas E Papantoniou ◽  
Peter D Papapetrou ◽  
Aristidis J Antsaklis ◽  
Panayotis E Kontoleon ◽  
Spyros A Mesogitis ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Reproductive Age ◽  
Fetal Life ◽  
Intact Parathyroid Hormone ◽  
Human Fetuses ◽  
Related Protein ◽  
Amino Terminal ◽  
Parathyroid Hormone Related Protein ◽  
Circulating Levels ◽  
Immunoreactive Parathyroid Hormone

Papantoniou NE, Papapetrou PD, Antsaklis AJ, Kontoleon PE, Mesogitis SA, Aravantinos D. Circulating levels of immunoreactive parathyroid hormone-related protein and intact parathyroid hormone in human fetuses and newborns. Eur J Endocrinol 1996;134:437–42. ISSN 0804–4643 Undetectable or extremely low levels of circulating immunoreactive parathyroid hormone (PTH) have been reported in human newborns while PTH bioactivity was high. This prompted the hypothesis that the fetal calcemic hormone might be PTH-related protein. The purpose of this study was to measure circulating immunoreactive PTH-related protein in human fetuses and newborns in order to investigate this hypothesis. Parathyroid hormone-related protein (PTHrP(1–86)) and intact PTH were measured using two-site immunoradiometric assays in plasma obtained by cordocentesis from 23 fetuses (19–33 weeks of gestation), from 17 newborns at term (38–41 weeks), from their mothers and from 22 normal women of reproductive age. Plasma PTHrP was detectable in all but one of the fetuses and newborns and in all the mothers and the controls. The mean level was similar among fetuses (19–33 weeks) (0.43 ± 0.18 pmol/l), newborns (0.48 ±0.12), mothers (0.48 ±0.14) and normal controls (0.46 ± 0.09). Plasma PTH was found to be significantly higher in fetuses at midgestation (1.0 ± 0.99 pmol/l) than in the newborns (0.22 ± 0.21) (p < 0.0025); maternal PTH was significantly higher compared to fetal level at mid-gestation (2.1 ± 1.0, p < 0.01) as well as at term (2.69 ± 1.40, p < 0.001). In the control women PTH was 3.07 ± 1.25 pmol/l. These results showed that plasma amino-terminal PTHrP-(1–86)) is detectable during the second half of human fetal life and its level remains unchanged during this period of time, in contrast to changing levels of fetal plasma PTH. The relatively low PTHrP-(1–86) level that we found in the newborns is not responsible for the high PTH-like bioactivity found by some investigators in cord blood at term. Peter D Papapetrou, Second Division of Endocrinology, "Alexandra" Hospital, 80 Vas. Sofias & Lourou Streets, Athens 115 28, Greece

scholarly journals Synthesis of a Biologically Active N-Terminal Tetratriacontapeptide of Parathyroid Hormone

1971 ◽  
Vol 68 (1) ◽  
pp. 63-67 ◽  
Author(s):  
J. T. Potts ◽  
G. W. Tregear ◽  
H. T. Keutmann ◽  
H. D. Niall ◽  
R. Sauer ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Biologically Active

The Circadian Rhythm of Intact Parathyroid Hormone-(1–84): Temporal Correlation with Prolactin Secretion in Normal Men

1990 ◽  
Vol 71 (6) ◽  
pp. 1556-1560 ◽  
Author(s):  
F. C. LOGUE ◽  
W. D. FRASER ◽  
D. ST. J. O'REILLY ◽  
D. A. CAMERON ◽  
A. J. KELLY ◽  
...  
Keyword(s):  
Circadian Rhythm ◽  
Parathyroid Hormone ◽  
Temporal Correlation ◽  
Prolactin Secretion ◽  
Intact Parathyroid Hormone ◽  
Normal Men

Effect of a protease inhibitor on in vitro stability of intact parathyroid hormone

2003 ◽  
Vol 40 (2) ◽  
pp. 188-190 ◽  
Author(s):  
N. R. Anderson ◽  
J. Nicholas ◽  
M. R. Holland ◽  
R. Gama
Keyword(s):  
Parathyroid Hormone ◽  
Protease Inhibitor ◽  
Protease Activity ◽  
Intact Parathyroid Hormone ◽  
In Vitro Degradation ◽  
Glass Tubes ◽  
Edta Plasma ◽  
In Vitro Stability ◽  
Baseline Sample

Background: We investigated whether increased protease activity explains the increased in vitro degradation of intact parathyroid hormone (iPTH) observed in serum when compared to EDTA plasma. Methods: Pre-dialysis blood samples for iPTH were taken from 11 patients with chronic renal failure and collected into plain glass tubes, tubes containing 200 KIU/mL aprotinin (a protease inhibitor) and EDTA tubes. All sample aliquots were separated at 20 min, 1 h, 2 h, 4 h, 8 h and 24 h post collection. Results: Over 24 h, iPTH concentrations remained unchanged in EDTA tubes. iPTH concentrations were significantly lower in both plain tubes ( P < 0·01) and aprotinin tubes ( P < 0·001) at 24 h when compared to the baseline sample (20 min). At 24 h, iPTH concentrations in EDTA tubes were higher than in plain tubes ( P < 0·001) and aprotinin tubes ( P < 0·01). The addition of aprotinin to plain tubes significantly reduced the degradation of iPTH ( P < 0·05) at 24 h. Conclusion: Aprotinin significantly reduces the in vitro degradation of iPTH in plain tubes at 24 h from 24·7% to 9·6%. We suggest that increased protease activity contributes to the decline in serum iPTH over time. As this is observed in serum and not plasma it suggests that the increased protease activity may be due to the clotting process.

scholarly journals Serum intact parathyroid hormone levels in cats with chronic kidney disease

2013 ◽  
Vol 33 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Luciano H. Giovaninni ◽  
Marcia M. Kogika ◽  
Marcio D. Lustoza ◽  
Archivaldo Reche Junior ◽  
Vera A.B.F. Wirthl ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Stage Iv ◽  
Control Group ◽  
Intact Parathyroid Hormone ◽  
Acid Base ◽  
Acid Base Status ◽  
Serum Ionized Calcium ◽  
Progression Of Renal Disease

Chronic kidney disease (CKD) is frequently observed in cats and it is characterized as a multisystemic illness, caused by several underlying metabolic changes, and secondary renal hyperparathyroidism (SRHPT) is relatively common; usually it is associated with the progression of renal disease and poor prognosis. This study aimed at determining the frequency of SRHPT, and discussing possible mechanisms that could contribute to the development of SRHPT in cats at different stages of CKD through the evaluation of calcium and phosphorus metabolism, as well as acid-base status. Forty owned cats with CKD were included and divided into three groups, according to the stages of the disease, classified according to the International Renal Interest Society (IRIS) as Stage II (n=12), Stage III (n=22) and Stage IV (n=6). Control group was composed of 21 clinically healthy cats. Increased serum intact parathyroid hormone (iPTH) concentrations were observed in most CKD cats in all stages, and mainly in Stage IV, which hyperphosphatemia and ionized hypocalcemia were detected and associated to the cause for the development of SRHPT. In Stages II and III, however, ionized hypercalcemia was noticed suggesting that the development of SRHPT might be associated with other factors, and metabolic acidosis could be involved to the increase of serum ionized calcium. Therefore, causes for the development of SRHPT seem to be multifactorial and they must be further investigated, mainly in the early stages of CKD in cats, as hyperphosphatemia and ionized hypocalcemia could not be the only factors involved.

Intact parathyroid hormone levels and primary hyperparathyroidism

2017 ◽  
pp. 1-5 ◽  
Author(s):  
Haidar Al-Hraishawi ◽  
Peter J. Dellatore ◽  
Xinjiang Cai ◽  
Xiangbing Wang
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Intact Parathyroid Hormone ◽  
Hormone Levels

Studies on the use of cultured cells in a bioassay for parathyroid hormone

1994 ◽  
Vol 143 (2) ◽  
pp. 261-268
Author(s):  
A E Armston ◽  
P J Wood
Keyword(s):  
Parathyroid Hormone ◽  
Cyclic Amp ◽  
Cell Line ◽  
Cultured Cells ◽  
Biologically Active ◽  
Kidney Cell Line ◽  
Opossum Kidney ◽  
Pre Treatment ◽  
Set Up ◽  
Insufficient Sensitivity

Abstract Measurement of parathyroid hormone (PTH) is important for diagnosing hyper- and hypoparathyroidism. The move to two-site immunometric assays that detect the whole molecule has improved the discrimination of these conditions but these assays may be too restrictive because some PTH fragments that are biologically active may not be detected. In addition, PTH-like peptide of malignancy, an important cause of malignancy-associated hypercalcaemia, is not detected by the two-site assays. Experiments were performed to set up a simple, robust and inexpensive bioassay for PTH, exploiting a kidney cell line and using cyclic AMP or an eluted stain assay as the end point. Of the 12 cell lines tested, an opossum kidney (WOK) cell line showed the most promise. Despite optimization of the procedure to include pre-treatment with dexamethasone, insulin and PTH, followed by incubation in the presence of 5′ -guanylimidodiphosphate, isobutyl-1-methylxanthine and forskolin, the WOK cells showed insufficient sensitivity for use in a cultured cell bioassay for PTH in human serum. In addition, the cells were less sensitive to PTH-like peptide precluding their use for an assay for this molecule. Journal of Endocrinology (1994) 143, 261–268

Sign in / Sign up

Export Citation Format

Share Document